Teva to buy Cephalon for $6.8 billion, topping Valeant's unsolicited bid
This article was originally published in Scrip
Executive Summary
Israeli generic king Teva Pharmaceutical Industries has agreed to buy the US biotech Cephalon for $6.8 billion in cash – topping an unsolicited bid by Valeant Pharmaceuticals.